Navigation Links
Experts Release New Cystic Fibrosis Guidelines
Date:11/15/2007

Includes updated info on which drugs work, which don't

THURSDAY, Nov. 15 (HealthDay News) -- Experts on Thursday issued new clinical standards for the treatment of cystic fibrosis (CF).

The guidelines were based on a two-year review of published research on patients aged six and older.

"Physicians treating patients with CF are faced with a growing number of treatment options. We are hopeful that clinicians will find these recommendations to be useful in their care of patients with CF," the guidelines' lead author, Dr. Patrick A. Flume, said in a prepared statement.

CF is a genetic disease that affects the lungs and other organs. It's characterized by thick, sticky mucus that makes it almost impossible for CF patients to fight off germs and infections. The disease is always fatal, and lung disease accounts for 85 percent of deaths among CF patients. However, advances in treatment in the last 60 years have increased life expectancy from just a few years to about 36 years.

Flume and his colleagues looked at a number of treatments and rated their effectiveness. Those with the strongest, most consistent results were given an "A" grade recommendation. They are:

  • Inhaled tobramycin -- an antibiotic -- to suppress chronic Pseudomonas aeruginosa infections in CF patients with moderate to severe disease, to improve lung function and reduce exacerbations.
  • Dornase alfa, which degrades the free DNA that accumulates in CF mucus, thereby loosening the mucus, promoting airway clearance, improving lung function and reducing exacerbations.

"B" grade recommendations were given for:

  • Inhaled tobramycin, to suppress Pseudomonas aeruginosa infections in CF patients with mild disease or who are asymptomatic, to reduce exacerbations.
  • Dornase alfa, for CF patients with mild disease who are asymptomatic, to improve lung function and reduce exacerbations.
  • Hypertonic saline, which hydrates surface liquid in patients with CF, thereby improving lung function and decreasing exacerbations.
  • Beta 2-adrenergic receptor agonists, which relax smooth muscles and dilate bronchial passages, which improve lung function in CF patients, and are well-tolerated.

The guidelines recommend against:

  • Systemic corticosteroids in children because of "an excess number of adverse events," including abnormalities in glucose metabolism, cataracts, and percentage of patients "colonized" with Pseudomonas. This recommendation excludes patients with concomitant asthma.
  • Inhaled corticosteroids, because there's no clinical benefit. This recommendation excludes patients who also have asthma, however.
  • Prophylactic anti-Staphylococcal antibiotics because of the lack of clinical efficacy and an apparent increase in P. aeruginosa infections with their use.

There wasn't sufficient evidence to recommend for or against other types of treatment, said Flume and his colleagues.

The guidelines are published in the second issue for November of the American Journal of Respiratory and Critical Care Medicine.

More information

The March of Dimes has more about cystic fibrosis.



-- Robert Preidt



SOURCE: American Thoracic Society, news release, Nov. 15, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach
2. MultiVu Video Feed: PUBLIC HEALTH EXPERTS CONVENE TO DISCUSS THE TREATMENT AND PREVENTION OF RABIES
3. Health IT Event Draws Experts to the Pacific Northwest
4. Experts Sort Out Good Fats From Bad
5. Experts Offer Tips on Lung Cancer Prevention
6. March of Dimes, Experts for Moms and Babies, Launches Podcast
7. World fertility experts to meet in Montreal - IVF and IVM patients to provide first-person accounts at 14th World Congress
8. Bay IVF Experts Launch One of First East-West Fertility Programs of Its Kind
9. Experts propose cholesterol tests at 15 months of age
10. Experts Publish New Lung Disease Guidelines
11. Experts, Advocates Available to Comment on Hillary Clintons Health Care Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: